The global Fiducial Marker market, prepared by Fact.MR, presents a detailed study on the market. The study has leveraged the benefits of various multi-disciplinary approaches [read full press release…]
A recently published market research report by Fact.MR on the Fiducial Marker Market depicts a crystal clear view of the market over the considered period [read full press release…]
A business intelligence report on the global Fiducial Marker market offers quantitative estimation of the opportunities and qualitative assessment various growth dynamics. The study highlights [read full press release…]
As per the recent research report published by Fact.MR, the global Fiducial Markers market is on course to achieve a highly eye-catching growth. The research report [read full press release…]
Fact.MR has adopted multi-disciplinary approach to shed light on the evolution of the global Fiducial Marker Market during the historical period of 2013 – 2017. [read full press release…]
Fiducial markers sales are anticipated to surpass 100 Mn by 2019, registering an upswing from 93.9 Mn in 2018, according to a Fact.MR study. As [read full press release…]
The global fiducial marker market study presents an all in all compilation of the historical, current and future outlook of the market as well as [read full press release…]
The global fiducial marker market reached ~US$ 93.9Mn in 2018 and is anticipated grow at a CAGR of 9% over the forecast period 2018-2028. In [read full press release…]
As per the Fact.MR study, the adoption of fiducial markers for prostate cancer have been witnessing a persistent increase, driven by their ability in terms [read full press release…]
A fiducial marker is a device designed to serve as a reference for physical comparison and positional verification of tissues during diagnostic and therapeutic applications [read full press release…]
A fiducial marker is a device designed to serve as a reference for physical comparison and positional verification of tissues during diagnostic and therapeutic applications [read full press release…]
